Evidence map›Paper›PMID 40131377›Full record

SynthesisRheumatology (Oxford, England)2025

Intracranial GCA: a comprehensive systematic review.

Sagar Patel, Iva Okaj, Jessica Scott, Sukhreet Atwal, Colin Stark, Rabia Tahir, Nader Khalidi, Mats Junek

Abstract readSystematic Review
In one paragraph

Synthesis in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sagar PatelDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-0897-9300
Iva OkajDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Jessica ScottDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Sukhreet AtwalDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Colin StarkDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Rabia TahirDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Nader KhalidiDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-8270-2617
Mats JunekDivision of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-8416-3955

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGCA is increasingly recognized to occur in intracranial vessels with unknown clinical ramifications. We identified all reported cases of intracranial GCA (ICGCA) in the literature to describe common presentations, investigations, treatments and outcomes.

methodsWe conducted a systematic review using MEDLINE (Medical Literature Analysis and Retrieval System Online), Embase and PubMed databases to identify studies that reported cases of ICGCA. The study was registered on a systematic review database (PROSPERO 42023412373). We defined intracranial involvement as any vessel cranial to the dura mater that was confirmed by either histopathology or imaging. Data were summarized using descriptive statistics.

resultsOf 1554 studies identified, 102 studies underwent full-text review. These studies included 340 patients with ICGCA. The median age was 73.7 (interquartile range [IQR] 71.9-77.3) and 46.9% patients were female. Presentations of ICGCA included stroke in 240 (70.6%) patients and isolated intracranial imaging or histologic changes in 67 (19.7%) patients. The most common vessels involved were 180 (52.9%) vertebrobasilar, 166 (48.8%) internal carotid and 49 (14.4%) ophthalmic arteries. Treatment was reported in 214 individuals. Glucocorticoids were administered to 210 (98.1%); tocilizumab, cyclophosphamide and methotrexate were the most common adjunctive medications. Of the 181 patients with reported follow-up outcomes, relapse occurred in 40 (22.1%) patients and 59 (32.6%) individuals died.

conclusionOur findings suggest that ICGCA is not a rare entity and may represent a more severe manifestation of GCA. Optimal therapy for ICGCA is unknown. Structured prospective evaluation is needed to better understand this manifestation of GCA.

Indexed as

Giant Cell ArteritisAgedFemaleHumansMalebraindiagnostic imagingGCAsystematic reviewvasculitis

Identifiers

PMID40131377
PMCPMC12316374

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.